Trade BBIO stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
BridgeBio Pharma, Inc. (BBIO) is trading at US$68.38, down 5.52% today as of Sep 15, 16:00 EDT. The company has a market capitalisation of US$15.93B. Over the past 52 weeks, BBIO has traded between US$48.78 and US$93.42. On Syfe you can trade BBIO with $0 commission and add it to your watchlist.
| Previous close | US$72.38 |
|---|---|
| Market cap | US$15.93B |
| 52-week range | US$48.78 – US$93.42 |
| Volume | 1.84M |
| Exchange | US |
Add to Watchlist
Set Price Alert
BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Francis Patrick McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.
Year: 2019
BridgeBio Pharma's Transition to Rare Disease 'Commercial Powerhouse' On Track, RBC Says
Aug 14, 3:20 PM · MT Newswires
BridgeBio Pharma, Inc. (BBIO) stock is trading at US$68.38, -5.52% from the previous close of US$72.38.
The market cap for BridgeBio Pharma, Inc. (BBIO) stock is approximately US$15.93B.
The 52-week high for BridgeBio Pharma, Inc. (BBIO) stock is US$93.42.
The 52-week low for BridgeBio Pharma, Inc. (BBIO) stock is US$48.78.
BridgeBio Pharma, Inc. (BBIO) does not currently pay a dividend.
Stay on top of BBIO
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
Popular Stocks in Singapore
